Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

[News]

Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVexTM lentiviral vector platform.

More... (http://www.news-medical.net/news/20140605/Immune-Design-begins-treatment-in-LV305-Phase-1-clinical-trial-for-cancer.aspx)